Barasertib (AZD1152-HQPA)

Catalog No.S1147 Synonyms: AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib

For research use only.

Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Selleck's Barasertib (AZD1152-HQPA) has been cited by 102 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Other Aurora Kinase Products

Biological Activity

Description Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets
Aurora B [1]
(Cell-free assay)
0.37 nM
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP NXKxSJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH4NE02ODBibl2= M33ySlQ5yqCq MkTITWM2OD1{NTDuUS=> M3\0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OlU6Lz5{NUK3O|Y2QTxxYU6=
LNCaP NIjnWHBCeG:ydH;zbZMhSXO|YYm= NUHkO5U3OC13MECgcm0> NFe1V4E1QMLiaB?= NIjaeVBqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRpKHSqcn;1[4gh[2G|cHHz[U0{KHWycnXneYxifGmxbh?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
LNCaP MXjGeY5kfGmxbjDBd5NigQ>? NFrGWnA2OCCwTR?= M4DSWVQ5KGh? NEfJb2ZqdmS3Y3XzJI1q[3KxboXjcIVqKHerdHigZY5mfWenbnnjJI1m[2ijbnnzcS=> NH\PW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Y2QSd-MkWyO|c3PTl:L3G+
Ramos NVnE[IV5TnWwY4Tpc44hSXO|YYm= MnjqOVAxKG6P MoHsNE04OiCq NVfucnVTcW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl M4rsOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Daudi  M1jpTGZ2dmO2aX;uJGF{e2G7 NEXPe5k2ODBibl2= NYDFOY9KOC15MjDo NXqwRlB3cW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L540 M3jYXmZ2dmO2aX;uJGF{e2G7 MnzuOVAxKG6P NYnFT2ZOOC15MjDo NU\FPFZJcW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl M{TIUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
BJAJ Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXtRpdmPTByIH7N NWDPbYZ5OC15MjDo NXjhd|M{cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Ramos M4fyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGxOVAxKG6P Mom4NE04OiCq MkjLbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETLb402ODBibl2= M{mzVFAuPzJiaB?= M{PEV4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NWLYU4c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Daudi  MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LvXlUxOCCwTR?= MoDsNE04OiCq NX;y[WhtcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> NHzjNnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L428 NYLk[Y93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX6[3k{PTByIH7N MX:wMVczKGh? M1\GXYlvcGmkaYTzJINmdGxiZ4Lve5Rp M2S3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
KM-H2 M2XSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV21NFAhdk1? MkH3NE04OiCq NVjFW5ZZcW6qaXLpeJMh[2WubDDndo94fGh? M4rSSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
HDLM-2 NFW3Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf5ZVBOPTByIH7N MnziNE04OiCq M{nkPIlvcGmkaYTzJINmdGxiZ4Lve5Rp NV\ne3FuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
L450 NHfxTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TTSlUxOCCwTR?= NUnMPWs{OC15MjDo NGD5PFdqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
BJAJ MmDGRZBweHSxc3nzJGF{e2G7 NWPmfJN{PTByIH7N M4jjdFAuPzJiaB?= MkLSbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M33aVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Ramos MnrRRZBweHSxc3nzJGF{e2G7 NVrZVWU4PTByIH7N NUHON2lnOC15MjDo M{\hZ4lv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Raji NUXEUXZlSXCxcITvd4l{KEG|c3H5 M3LGU|UxOCCwTR?= MVWwMVczKGh? Mo\JbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Daudi  NF;LTWZCeG:ydH;zbZMhSXO|YYm= MXW1NFAhdk1? NH7WOHAxNTd{IHi= NVLTWY46cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L428 MoHuRZBweHSxc3nzJGF{e2G7 NWT4NFgyPTByIH7N MWiwMVczKGh? M2LPNolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHz4emI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
KM-H2 MWrBdI9xfG:|aYOgRZN{[Xl? M3nTSFUxOCCwTR?= MmiyNE04OiCq NYraTIRwcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NV6zNFFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
HDLM-2 NHXYfXVCeG:ydH;zbZMhSXO|YYm= MXW1NFAhdk1? MXiwMVczKGh? NX;rTpBqcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NGPzU5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L450 NUPhb2xPSXCxcITvd4l{KEG|c3H5 M4[2Z|UxOCCwTR?= NYHZTYV7OC15MjDo MoXhbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NIryNHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
SW620 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLufYt4TUN3ME2xNOKyOi5zIH7N M4TRWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkS1NFkxLz5{MUK0OVA6ODxxYU6=
HCT116 M2KwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC0bVN1TUN3ME2xNeKyOy5|IH7N NUjydGlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOFUxQTBpPkKxNlQ2ODlyPD;hQi=>
MDA-MB-435 NF7INpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfncZpoOC1zMECwNEBvVQ>? NFz5d|IzNTViZB?= NUjoN201TE2VTx?= NELVSY1KSzVyPUGyOUBvVQ>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-468 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKwMVExODByIH7N MoHxNk02KGR? NI\p[lRFVVOR M1q2UGlEPTB;MUSgcm0> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-231 NXLiWZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXqNE0yODByMDDuUS=> MX:yMVUh\A>? Moj3SG1UVw>? M2ewdWlEPTB;MUC1JI5O Mn[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
BT474 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMVExODByIH7N NITQdmwzNTViZB?= MmXjSG1UVw>? MXjJR|UxRThibl2= NGnGRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-361 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6dVAuOTByMECgcm0> NVzZVYg2Oi13IHS= MmLqSG1UVw>? NFK5V5lKSzVyPUewJI5O M3y1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
HER18 M{XjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3XmdnOC1zMECwNEBvVQ>? MXyyMVUh\A>? Ml;MSG1UVw>? MnTGTWM2OD1{MDDuUS=> NYXFcmliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
HER18 MVHBdI9xfG:|aYOgRZN{[Xl? NXu5VFZzOTByIH7N MnvzNE8zPC92ODDo M{fTSWROW09? NFHYS5JqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= NFPnb2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-231 Mly5RZBweHSxc3nzJGF{e2G7 MoP2NVA2KG6P MkTvNE8zPC92ODDo MmLoSG1UVw>? NISwXpNqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= NGPoXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
JHH-1 NEH4fm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L1[FAvO+LCk{GwNFDDqG6P MmnTO|IhcA>? M3XEZ2VEPTB;MUeuOOKyOS5yIH7N MnvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
JHH-2 NHzufYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvvfZVrOC5|4pETNVAxOMLibl2= NGLVXIg4OiCq NFPTTpNGSzVyPUKxPE4xyrFzMD64JI5O NIn4Z|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
JHH-4 NIX5OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNNE4{6oDVMUCwNOKhdk1? Mnr6O|IhcA>? M2rQPGVEPTB;MUW1MlbDuTF4Lkigcm0> M{PSRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-1 M1O0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnydHcxNjQkgKOxNFAxyqCwTR?= M1HX[lczKGh? M2Wx[mVEPTB;MkeuN:KyPS5yIH7N NULzbnBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HuH-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWeyWmtTOC5|4pETNVAxOMLibl2= MoDGO|IhcA>? NH:xcHdGSzVyPUOuO:KyOC54IH7N M1HmU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-7 M4O2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPJUIYxNjQkgKOxNFAxyqCwTR?= Ml7nO|IhcA>? NU[1OlE3TUN3ME22MljDuTBwMzDuUS=> M3LWZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HLE NIq0d5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDCU3gxNjQkgKOxNFAxyqCwTR?= NVvE[lBzPzJiaB?= MYfFR|UxRTR3LkpCtVYvPCCwTR?= NF2zeZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HLF NF[wdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnRRWtZOC5|4pETNVAxOMLibl2= NVPXblhmPzJiaB?= M2PKc2VEPTB;MUK2MlHDuTF{LkKgcm0> MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
PLC/PRF/5 NUjJ[HBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKwMlPjiJNzMECwxsBvVQ>? M3\FW|czKGh? M4D6NGVEPTB;N{[uPeKyQS57IH7N NXTRPXV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
SK-Hep1 NWDaZ5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHCNE4{6oDVMUCwNOKhdk1? M4jiOFczKGh? MmPtSWM2OD1{MT65xtEyNjJibl2= M{HkV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
Hep3B M3uzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UXoxROC5|4pETNVAxOMLibl2= M1XqOlczKGh? NEjGO41GSzVyPUeuOuKyOS5{IH7N NULDVVNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HepG2 M33MRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMlPjiJNzMECwxsBvVQ>? MXm3NkBp M3TibmVEPTB;MUSuO:KyOS55IH7N NGLqSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
Ramos MWHBdI9xfG:|aYOgRZN{[Xl? MVSyOU82OC9zMECgcm0> MXm0PEBp M4W0O4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh{M{G2PEc,OTl6MkOxOlg9N2F-
Daudi  NUmw[3N[SXCxcITvd4l{KEG|c3H5 M1rLXVI2NzVyL{GwNEBvVQ>? MXm0PEBp MY\pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MkOxOlgoRjF7OEKzNVY5RC:jPh?=
BALM-14 MYfBdI9xfG:|aYOgRZN{[Xl? M4H2bFEzNjVxMkWvOVAhdk1? MnK3OFghcA>? NFmyTG1qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> MlLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MkOxOlgoRjF7OEKzNVY5RC:jPh?=
BALM-27 M2DYZmFxd3C2b4Ppd{BCe3OjeR?= MXexNk42NzJ3L{WwJI5O MU[0PEBp MVfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= M1vqWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
NB4 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSxZ|VYOC5yMT:wMlEwOSEQvF2= MofpOFghcA>? M2nCeYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M1HHTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[3OFg1Lz5zOEO2O|Q5PDxxYU6=
HeLa NF3UXZRHfW6ldHnvckBCe3OjeR?= M3zLWVEhfU1? M1;jSFI1KGi{cx?= NEPoOZNKdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW0PUc,OjB4OES1OFk9N2F-
Assay
Methods Test Index PMID
Western blot AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN ; p53 / p21 / p-p38 / p38 26497213 24782314
Immunofluorescence p21 24782314
Growth inhibition assay Cell viability 26497213

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 102 mg/mL
(200.96 mM)
Water Insoluble
Ethanol '3 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

7mg/mL

Chemical Information

Molecular Weight 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03217838 Terminated Drug: AZD2811|Drug: Azacitidine|Drug: Venetoclax Acute Myeloid Leukaemia AstraZeneca November 27 2017 Phase 1|Phase 2
NCT02579226 Completed Drug: AZD2811 Advanced Solid Tumours AstraZeneca October 28 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

Answer:
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor